Journal
Neurology and Therapy
Publication Date
12-1-2023
Volume
12
Issue
6
First Page
1937
Last Page
1958
Document Type
Open Access Publication
DOI
10.1007/s40120-023-00533-1
Rights and Permissions
Aldred, J., Freire-Alvarez, E., Amelin, A.V. et al. Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study. Neurol Ther 12, 1937–1958 (2023). https://doi.org/10.1007/s40120-023-00533-1 This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Recommended Citation
Aldred, Jason; Criswell, Susan R; and et al., "Continuous subcutaneous foslevodopa/foscarbidopa in Parkinson's disease: Safety and efficacy results from a 12-month, single-arm, open-label, phase 3 study." Neurology and Therapy. 12, 6. 1937 - 1958. (2023).
https://digitalcommons.wustl.edu/oa_4/2842
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
Correction
